Q-omics provides the consensus-scored STK25P1 profile across patient tissues and cancer cell-line models. STK25P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, STK25P1 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, STK25P1 RNA expression shows 14,533 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CESC, KICH, and DLBC as cancer lineages where STK25P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK25P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK25P1 survival associations across molecular data types. STK25P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK25P1 RNA expression–survival associations across cancer types. High STK25P1 expression shows unfavorable associations in CESC, UVM and ACC, but favorable associations in LUAD, ESCA and HNSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for STK25P1 RNA expression.
This table summarizes STK25P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for STK25P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK25P1 shows lower tumor expression in KICH, KIRC, THCA, KIRP and BRCA and higher tumor expression in HNSC. The KICH box plot shows higher STK25P1 RNA expression in normal versus tumor tissue (log2 FC = −0.570, t-test p < 0.001).
This table shows molecular features associated with STK25P1 in patient tissues and cancer cell lines. In patient samples, STK25P1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
